Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Rhythm Pharmaceuticals

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

33 Stocks Moving In Friday's Mid-Day Session

Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.

5 Analysts Have This to Say About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals (NASDAQ:RYTM) has observed the following analyst ratings within the last quarter:

Rhythm Pharmaceuticals' Shares Dive Following FDA's Verdict On IMCIVREE Drug

The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ (NASDAQ: RYTM) supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).

Expert Ratings for Rhythm Pharmaceuticals

Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Rhythm Pharmaceuticals's Return On Capital Employed Insights

Rhythm Pharmaceuticals's Return On Capital Employed Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) brought in sales totaling $1.50 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 23.09%, resulting in a loss of $52.76 million.

Rhythm Pharmaceuticals: Q1 Earnings Insights

Rhythm Pharmaceuticals: Q1 Earnings Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Rhythm Pharmaceuticals Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET

Rhythm Pharmaceuticals Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET

Rhythm Pharmaceuticals (NASDAQ:RYTM) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Rhythm Pharmaceuticals (RYTM) Conference Call Follow this link to access the live webcast.

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

Rhythm Pharma Shares Fall After Modifications To Setmelanotide Trials In Rare Diseases of Obesity

Rhythm Pharma Shares Fall After Modifications To Setmelanotide Trials In Rare Diseases of Obesity

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM)

Expert Ratings For Rhythm Pharmaceuticals

Expert Ratings For Rhythm Pharmaceuticals

Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter:

Rhythm Pharmaceuticals Earnings Perspective: Return On Capital Employed

Rhythm Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q4 sales of $1.82 million. Earnings fell to a loss of $42.87 million, resulting in a 22.1% decrease from last quarter.

Get all your
news in one place.

100’s of premium titles.
One news app.

Rhythm Pharmaceuticals: Q4 Earnings Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Thinking About Buying Stock In Lucid Group, Rhythm Pharmaceuticals Or Kohl's?

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.

A Preview Of Rhythm Pharmaceuticals's Earnings

Rhythm Pharmaceuticals (NASDAQ:RYTM) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that Rhythm Pharmaceuticals will report an earnings per share (EPS) of $-0.91.

Organisations

Reliance Industries

Rhythm Pharmaceuticals

Sunshine Biopharma

Evofem Biosciences

Quoin Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

307,057 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play